WithdrawnNot Applicable

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

Stopped: No participants enrolled

United States0Started 2022-09-22

Plain-language summary

The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Failed allograft requiring dialysis * No living donor available for re-transplant option or anticipated deceased donor within the next 12 months * Patient to be enrolled prior to 3rd HD (hemodialysis) session or within 1 week of starting peritoneal dialysis Exclusion Criteria: * 17 years or younger * cPRA at entrance of 100% * Primary non-function of the allograft * Multi-organ transplant

What they're measuring

cPRA Concentrations

Timeframe: 1 day

cf-DNA Concentrations

Timeframe: up to 24 weeks

Trial details

NCT IDNCT04560582

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-09

View on ClinicalTrials.gov More Kidney Transplant; Complications trials